Skip to main content
COR
NYSE Trade & Services

Cencora Recasts Financials Into Three New Segments Starting Fiscal 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$345.75
Mkt Cap
$64.977B
52W Low
$244.82
52W High
$377.54
52W Position info
41% above low
Off High info
8.4% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

COR sits 41% above its 52-week low of $244.82.

Summary

Cencora will report under three new segments beginning fiscal 2027 and furnished recast FY2025/FY2026 segment revenue and operating income to match. The recast shows the specialty business earning a much richer margin than core distribution, and puts MWI Animal Health, Profarma and parts of PharmaLex in an 'Other' bucket under strategic review.


Key Events · Corporate Governance and Compliance · COR

  • Three New Reporting Segments From Fiscal 2027

    Beginning Q1 fiscal 2027, Cencora reports Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other, replacing the prior U.S. and International Healthcare Solutions segments.

  • Recast FY2026 Revenue by Segment

    Pharmaceutical Distribution and Services $284.48B, Specialty Pharmaceutical and Provider Services $45.39B, Other $8.74B, less $1.22B intersegment eliminations, for total revenue of $337.40B.

  • Margin Gap Between Segments

    FY2026 segment operating income was $2.74B on distribution (0.96% of revenue) versus $1.69B on specialty (3.73%), with Other at $392.9M (4.50%); total segment operating income was $4.81B.

  • Divestiture Candidates Grouped in 'Other'

    The non-reportable Other bucket holds businesses under strategic alternatives — MWI Animal Health, Profarma, and the remaining PharmaLex components.


Analysis · COR · Trade & Services

The margin mix is the key read-through here. Cencora has reorganized its operating model and will report under three segments from fiscal Q1 2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. To give investors a comparable baseline, the filing provides recast FY2025 and FY2026 numbers. On that recast basis, the distribution segment runs at roughly 0.96% operating margin on $284.5B of FY2026 revenue, while Specialty Pharmaceutical and Provider Services earns about 3.73% on $45.4B — meaning the specialty business carries far more profit per dollar of revenue. Separately, MWI Animal Health, Profarma and parts of PharmaLex are now parked in 'Other' as businesses under strategic alternatives, which frames potential divestitures. Because this lands the same day as the Q4 beat and FY2027 guidance, it serves as the reporting lens for that guidance rather than a new earnings event.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, COR was trading at $345.75 on NYSE in the Trade & Services sector, with a market capitalization of approximately $65B. The 52-week trading range was $244.82 to $377.54. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

COR - Latest Insights

COR
Nov 13, 2026, 11:43 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $356.14
Real-time Price: $347.86 info
Change: -$8.27 (-2%) info
Market Cap: $66.431B info
COR
Nov 04, 2026, 6:37 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $342.67
Real-time Price: $347.86 info
Change: +$5.19 (+2%) info
Market Cap: $66.431B info
COR
Nov 04, 2026, 6:35 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $343.67
Real-time Price: $347.86 info
Change: +$4.19 (+1%) info
Market Cap: $66.431B info
COR
Oct 21, 2026, 7:48 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $342.51
Real-time Price: $347.86 info
Change: +$5.35 (+2%) info
Market Cap: $66.431B info
COR
Oct 21, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $342.51
Real-time Price: $347.86 info
Change: +$5.35 (+2%) info
Market Cap: $66.431B info